Loading stock data…
TOI
$4.05+0.19 (+4.92%)
Market ClosedLast close May 1
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
The Oncology Institute, Inc. in the Healthcare sector is trading at $4.05. The stock is currently 17% below its 52-week high of $4.88, remaining 17.7% above its 200-day moving average. Technical signals show overbought RSI of 76 and bullish MACD crossover, explaining why TOI maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 76) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.05
Potential Upside
5%
Whystock Fair Value$4.25
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
The Oncology Institute, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$340.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.20
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
385.53%
Volume
Today's trading volume
2.23M
Recent News
Ensign Group (ENSG) Q1 Earnings Surpass Estimates
Ensign Group (ENSG) delivered earnings and revenue surprises of +3.35% and -0.07%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Here’s What Powered The Oncology Institute’s (TOI) Gains
Michigan-based investment advisor Cedar Grove Capital Management recently released its first quarter 2026 investor letter. A copy of the letter can be downloaded here. Cedar Grove Capital Management’s Multi-Strategy Composite posted a -23.0% net return since inception, compared to -5.6% for the Russell 2000, -5.9% for the Russell Microcap, and -5.5% for the S&P 500. […]
TSX Stocks Including Montage Gold That May Be Trading Below Intrinsic Value Estimates
As the Canadian TSX index has shown resilience, rebounding from recent lows alongside the S&P 500, investors are cautiously optimistic despite ongoing uncertainties and elevated oil prices. In this environment, identifying stocks that may be trading below their intrinsic value can offer potential opportunities for those looking to navigate market fluctuations effectively.
One Oncology Institute Insider Raised Their Stake In The Previous Year
Looking at The Oncology Institute, Inc.'s ( NASDAQ:TOI ) insider transactions over the last year, we can see that...
Oncology Institute (TOI) Earnings Transcript
Daniel Virnich: Thank you, Mark. Good afternoon, everyone, and thank you for joining our fourth quarter and full year 2025 earnings call. Most importantly, the fourth quarter marked an important milestone being our first profitable quarter as a public company from an adjusted EBITDA perspective.